TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$3.01 USD
+0.04 (1.35%)
Updated Apr 24, 2024 03:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
TFFP 3.01 +0.04(1.35%)
Will TFFP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TFFP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TFFP
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
TFFP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
Other News for TFFP
TFF Pharmaceuticals files to sell 147,500 shares of common stock for holders
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals announces data from TFF TAC Phase 2 trial
TFF Pharmaceuticals files to sell common stock, warrants
TFF Pharmaceuticals files to sell common stock, warrants, no amount given